The RAS-RAF-MEK-extracellular signal–regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy.
Eribulin mesylate has demonstrated clinical benefit as a first-line therapy for locally recurrent or metastatic HER2- negative breast cancer, according to results of a phase II, multicenter, single-arm study.
Significant developments in research and treatment for HER2-positive breast cancer have emerged over the past year. Those advances include a growing number of studies measuring the effectiveness of dual agents.